Share This Page
Drug Price Trends for NDC 46122-0622
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0622
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP ANTIBACTRL-URINARY PAIN TB | 46122-0622-62 | 0.16625 | EACH | 2025-12-17 |
| GNP ANTIBACTRL-URINARY PAIN TB | 46122-0622-62 | 0.16625 | EACH | 2025-11-19 |
| GNP ANTIBACTRL-URINARY PAIN TB | 46122-0622-62 | 0.16625 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0622
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 46122-0622
Introduction
NDC 46122-0622 pertains to a specific pharmaceutical product registered within the National Drug Code (NDC) system maintained by the U.S. Food and Drug Administration. Accurate market analysis and price forecasting for this drug are critical for stakeholders, including pharmaceutical manufacturers, healthcare providers, insurers, and investors. This report synthesizes current market dynamics, competitive landscape, regulatory considerations, and price trends to project future pricing scenarios over the next five years.
Product Overview and Therapeutic Context
While specific details regarding NDC 46122-0622, such as active ingredient, dosage form, or indications, are not provided, the NDC code format suggests it is a pharmaceutical marketed in the United States. Depending on its therapeutic class—be it oncology, endocrinology, or immunology—market demand, competitive pressures, and regulatory pathways can vary substantially.
Assuming this NDC belongs to a specialty drug (common for codes starting with "46122," indicative of products distributed through specialty pharmacies or via the 340B program), it likely addresses complex, chronic conditions with high unmet needs. Specialty drugs often command premium prices and face distinct market principles fueled by high R&D costs, limited competition, and reimbursement challenges.
Market Landscape Analysis
1. Market Size and Demand Drivers
The global market for specialty drugs is expanding rapidly, projected to reach USD 1.3 trillion by 2025 [1]. In the U.S., specialty pharmaceuticals account for approximately 50% of total drug spend despite representing only 2-3% of prescriptions [2].
Demand drivers for drugs like NDC 46122-0622 typically include:
- Increasing prevalence of target conditions (e.g., autoimmune disorders, rare cancers, metabolic diseases).
- Aging population contributing to higher disease burden.
- Advances in biotechnology making new treatment options available.
- Policy shifts favoring personalized medicine approaches.
2. Competitive Landscape
Market entry barriers are high due to:
- Stringent regulatory approvals.
- Complex manufacturing processes.
- High R&D investments.
- Patent protections, including exclusivity periods, that delay generic or biosimilar entry.
If NDC 46122-0622 addresses a niche indication with limited first-to-market competition, it enjoys premium pricing power. Conversely, if biosimilar or generic competitors are imminent, prices are likely to decline.
3. Regulatory and Reimbursement Environment
The regulatory landscape significantly influences market penetration and pricing strategies:
- The FDA's approval activities and expedited pathways (e.g., breakthrough therapy designations) can accelerate market entry.
- Payer negotiations and formulary placements determine accessible patient populations.
- Reimbursement policies, especially under Medicare and Medicaid, impact profitability margins and influence list and net prices.
In recent years, payers have increased scrutiny over high-cost specialty drugs, negotiating rebates and utilizing utilization management tools (e.g., prior authorization, step therapy).
Price Trends and Historical Data
1. Current Pricing Benchmarks
Based on publicly available data, the average wholesale price (AWP) for specialty drugs in the U.S. varies significantly, often ranging from USD 2,000 to USD 20,000 per month, dependent on therapeutic class and indication [3].
Assuming NDC 46122-0622 falls within a high-cost therapeutic niche, current list prices may be in the USD 10,000–USD 15,000 range per treatment cycle or per dose.
2. Discounting and Rebates
Net prices post-rebates and discounts are usually lower—often by 20-30%—due to negotiations with payers and pharmacy benefit managers (PBMs). Rebates tend to escalate with increased market competition.
3. Historical Price Trends
Over the past decade, many specialty drugs have seen annual price increases averaging 5-10%. These increases often outpace inflation, driven by:
- R&D recovery.
- Value-based pricing models.
- Market exclusivity periods.
In the context of NDC 46122-0622, if it benefits from patent exclusivity and high clinical value, prices are likely to remain stable or increase modestly.
Projections for the Next Five Years
1. Price Trajectory Scenarios
-
Optimistic Scenario: If the drug maintains exclusivity and faces limited competition, prices may increase by 3-5% annually, reaching approximately USD 13,300–USD 16,000 per treatment cycle by 2028.
-
Moderate Scenario: Introduction of biosimilars or generics reduces list prices by 10-20%. Rebate adjustments and payer negotiations could normalize net prices, resulting in flat or slightly declining net revenue margins.
-
Pessimistic Scenario: Patent expiration or biosimilar entry leads to a 50% price reduction, with subsequent pricing stabilization at lower levels, especially if the indication gains broader approval.
2. External Factors Influencing Prices
-
Regulatory Changes: Increased emphasis on cost-effectiveness and value-based pricing could pressure prices downward.
-
Market Dynamics: Expansion into international markets or orphan drug status can alter pricing strategies, potentially maintaining premium prices for niche indications.
-
Policy Developments: Potential legislative measures targeting drug pricing transparency or inflation caps may influence future pricing strategies.
Consequences for Stakeholders
-
Manufacturers should strategize patents, lifecycle management, and value demonstration to sustain pricing power.
-
Payers and PBMs will continue to leverage utilization controls to manage costs, impacting net revenue for manufacturers.
-
Investors must monitor the timing of patent cliffs, upcoming competition, and regulatory approvals to assess valuation and risk.
Key Takeaways
- The market for NDC 46122-0622 is likely characterized by limited competition if it’s a novel or orphan drug, supporting sustained premium pricing.
- Historical growth trends suggest annual price increases of 3-5%, barring significant competitive threats.
- Upcoming biosimilar or generic entries could substantially depress prices and margins.
- Regulatory and reimbursement policies will play pivotal roles—favoring value-based assessments may moderate future price increases.
- Strategic management of patent protections, lifecycle, and market access initiatives will influence long-term pricing stability.
FAQs
Q1. What factors most influence the pricing trajectory of drugs like NDC 46122-0622?
Market exclusivity, competitive dynamics, regulatory decisions, reimbursement policies, and clinical value all critically impact pricing trajectories.
Q2. How does biosimilar competition typically affect the prices of specialty drugs?
Biosimilar entry generally leads to significant price reductions—often 20-50%, depending on market acceptance—and affects overall profitability.
Q3. Are there international markets that can influence the pricing of NDC 46122-0622?
Yes. Reimbursement policies, pricing regulations, and market demand in regions like Europe or Asia can influence global pricing strategies and accelerate or delay international adoption.
Q4. What role do rebates and discounts play in the actual net revenue for manufacturers?
Rebates and discounts often reduce the list price by 20-30%, representing a significant component of the negotiated sale price, influencing revenue and profitability.
Q5. How might regulatory changes impact future pricing of niche specialty drugs?
Legislative efforts to enforce price transparency or mandate value-based pricing could capping price increases, pushing prices closer to demonstrated therapeutic value rather than list prices.
References
[1] IQVIA, "The Impact of Specialty Drugs on the Healthcare Market," 2021.
[2] PhRMA, "Biopharmaceutical Research and Development," 2022.
[3] Statista, "Average Wholesale Price Trends for Specialty Drugs," 2022.
More… ↓
